# Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease

> **NCT04491734** · NA · COMPLETED · sponsor: **ISOThrive Inc.** · enrollment: 156 (actual)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DIETARY_SUPPLEMENT:** maltosyl-isomalto-oligosaccharides (MIMO)

## Key facts

- **NCT ID:** NCT04491734
- **Lead sponsor:** ISOThrive Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2021-08-26
- **Final completion:** 2021-08-26
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04491734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04491734, "Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04491734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*